The concept of Quality by Design reflects the current regulatory viewpoints on pharmaceutical products globally. Improvement of performance is necessary for the pharmaceutical industry. It is necessary to introduce new technologies that can reduce costs and improve product quality at the same time. Quality by design (QbD) is the most effective approach to guaranteeing quality in every pharmaceutical product. The main objective of QbD is to ensure a top-quality product by combining current understanding with latest evaluations during the development phase. Both the FDA and ICH are strongly supporting the implementation of QbD. Quality by Design (QbD) in the pharmaceutical sector centers on understanding how materials and process parameters affect the quality of final products. This review examines key components of Quality by Design (QbD) like Target product quality profile, Critical quality attributes, Risk assessment, Design space, and Control strategy to understand how dosage forms function within the specified design space. QbD also deals with tools like DoE, Quality risk management, and process analytical technology. These criticisms highlight the importance of QbD in promoting a scientific mindset in the creation of pharmaceutical products.